rtmark
LearnBonds.com

Is Pfizer Inc. Bidding for Swedish Orphan Biovitrum?

Pfizer NYSE:PFE

Pfizer Inc. (NYSE:PFE) is expected to be secretly bidding for Swedish Orphan Biovitrum AB(STO:SOBI), a Sweden-based pharmaceutical company, engaged in developing hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, as per a Thomson Reuters report.

Earlier this week, Swedish Orphan Biovitrum has disclosed that it has received a preliminary and conditional non-binding proposal from a potential buyers. Swedish Orphan Biovitrum’s shares surged 32.7% in the last five days, and over 90% in the last 52 weeks. Swedish Orphan Biovitrum AB (STO: SOBI) has a market value of $36.2 billion, as per the April 30, 2015 closing price.

Competing with Biogen

Although Swedish Orphan Biovitrum AB (STO: SOBI) did not reveal bidders, Analysts estimated Pfizer and Biogen Inc(NASDAQ:BIIB) to be potential bidders. Sobi is engaged in developing ReFactor AF, a hemophilia treatment, which is sold by Pfizer.

Sobi deferred its annual shareholder meeting to June 30, 2015, due to its takeover proposal, which was otherwise planned on May 6, 2015. Meanwhile, Richard Koch, analyst from Kepler Cheuvreux expects that Sobi’s bid might be in the range of 140-150 Swedish crowns per share, worth approximately in the range of 37 billion crowns to 40 billion crowns (around US$4.3 billion).

Sobi has partnership with Biogen in North Africa, Europe, Russia, and parts of Middle East regions, for its hemophilia franchise, with the partnership estimated to be over $3.7 billion. Recently, Sobi’s, Elocta (rFVIIIFc), its long-acting rare-disease hemophilia drug candidate, received orphan drug designation in Switzerland.

To see a list of high yielding CDs go here.

Pfizer looks at rare diseases

Pfizer Inc. (NYSE:PFE) has set up a Rare Disease Research Unit to capture the opportunity in drugs for rare diseases. Mikael Dolsten, president of Worldwide Research and Development at Pfizer said “The fundamental understanding of the biology of hereditary rare diseases, coupled with advances in the technology to harness disarmed viruses as gene delivery vehicles, provide a ripe opportunity to investigate the next wave of potential life-changing therapies for patients. By establishing our gene therapy capabilities, we hope to gain a deeper understanding of the mechanisms that could potentially bring true disease modification for those suffering from devastating hematologic and neuromuscular diseases.”

Pfizer is seeking to acquire companies to grow its business, and have recently announced to buy Hospira Inc worth of $15 billion. The company’s attempt to acquire AstraZeneca Plc has failed last year. Pfizer’s CEO, Ian Read said that “he was open to deals and was agnostic about the size of acquisitions”, during the latest earnings call.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Adam Green is an experienced writer and fintech enthusiast. He he worked with LearnBonds.com since 2019 and covers a range of areas including: personal finance, savings, bonds and taxes.